Companies in #Neoantigen Therapy

Nouscom is a clinical-stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines on a proprietary viral-vector platform, including the NOUS-209 program in Lynch syndrome and neoantigen vaccines encoding hundreds of tumor-specific antigens. It operates from Basel, Switzerland and Rome, Italy.